Physician profile
B Todd Schaeffer
NPI 1336129550
$8,242.53
in general payments reported to CMS, 2019-2025
34 companies · $1,877 in 2025
The $1,877 reported for 2025 was more than what 92% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,107 · 2020: $346 · 2021: $656 · 2022: $1,386 · 2023: $1,597 · 2024: $1,274 · 2025: $1,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,747.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $1,740.35 | 2019-2025 | |
| Genzyme Corporation | $1,476.81 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,325.16 | 2021-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $1,140.80 | 2022-2025 | Dupixent |
| Intersect Ent, INC. | $453.17 | 2019-2022 | |
| Inspire Medical Systems, INC. | $289.91 | 2023-2025 | Inspire |
| Aerin Medical INC. | $215.32 | 2019 | |
| Blueprint Medicines Corporation | $176.19 | 2023-2024 | Ayvakit |
| Stryker Corporation | $175.30 | 2019-2024 | Audion Et Dilation System |
| Neurent Medical Limited | $171.62 | 2023 | Neuromark Radiofrequency Console, Neuromark Device |
| Genentech USA, INC. | $150.46 | 2024 | Xolair |
| Hikma Pharmaceuticals USA | $137.01 | 2022-2025 | Ryaltris |
| Arrinex, INC. | $120.10 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $85.87 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $81.43 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $61.56 | 2020-2023 | Trudi Nav Cable |
| Alk-Abello, INC | $59.44 | 2020-2022 | |
| Smith+Nephew, INC. | $52.73 | 2019 | |
| Pfizer INC. | $43.63 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $39.70 | 2023 | |
| Integra Lifesciences Corporation | $32.90 | 2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Acelrx Pharmaceuticals, INC. | $24.69 | 2022 | |
| Aimmune Therapeutics, INC. | $22.73 | 2020 | |
| Paratek Pharmaceuticals, INC. | $21.79 | 2025 | Xhance |
| Aytu Biopharma, INC. | $21.77 | 2020 | |
| Photonicare INC | $21.57 | 2024 | Otosight Middle Ear Scope |
| Octapharma USA, INC. | $19.61 | 2021 | |
| Circassia INC. | $18.89 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.63 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.66 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.09 | 2019 | |
| Allergan, INC. | $12.64 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw B Schaeffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.